I am not a doctor, ours is a pediatric study, theirs is for adults, they have another phase 2/3 pediatric study in progress, it should be compared with that when the data comes out
https://www.anavex.com/anavex-life-...he-treatment-of-adult-patients-with-rett-syn/
https://www.neurenpharma.com/irm/PD...ificantclinicalbenefitinpediatricRettsyndrome
https://www.clinicaltrials.gov/ct2/...&cond=Rett Syndrome&draw=2&rank=1
ANAVEX MEETS ENDPOINTS PHASE2 RETT, page-3
-
- There are more pages in this discussion • 164 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$14.19 |
Change
0.650(4.80%) |
Mkt cap ! $1.813B | |||
| Open | High | Low | Value | Volume |
| $13.65 | $15.24 | $13.63 | $19.05M | 1.328M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 5645 | $14.18 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.20 | 172 | 1 |
View Market Depth
| Last trade - 16.10pm 20/09/2024 (20 minute delay) ? |
| NEU (ASX) Chart |